Subtracting weight, nearly 80% is fat! Positive results of the new generation therapy announced
I'm PortAI, I can summarize articles.
Altimmune announced the clinical trial data of its investigational glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist pemvidutide for the treatment of obesity. The data showed that pemvidutide not only reduced weight but also maintained patients' muscle mass, with 21.9% of weight loss attributed to muscle mass and 78.1% to fat. The trial recruited 391 obese or overweight patients, and the results indicated a significant weight loss effect in the pemvidutide dose group. This is an important medical research achievement
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments